NICE update doubles eligible patients for AZ's Lokelma
AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
Newsletters and Deep Dive digital magazine
AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.
Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
Editor's Picks
Newsletters and Deep Dive
digital magazine